Filing Details

Accession Number:
0001140361-16-088417
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-12-01 16:59:01
Reporting Period:
2016-11-29
Filing Date:
2016-12-01
Accepted Time:
2016-12-01 16:59:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1445283 Proteostasis Therapeutics Inc. PTI Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1583977 Cormorant Asset Management, Llc 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
1599214 Bihua Chen C/O Cormorant Asset Management, Llc
200 Clarendon Street, 52Nd Floor
Boston MA 02116
Yes No Yes No
1618442 Cormorant Global Healthcare Master Fund, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
1618451 Cormorant Global Healthcare Gp, Llc 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-11-29 128,407 $10.28 3,508,352 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2016-12-01 41,984 $10.11 3,550,336 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Footnotes
  1. Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and by a managed account (the "Account"). Cormorant Asset Management, LLC ("Cormorant") serves as the investment manager of the Master Fund and the Account. Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant and GP LLC. GP LLC may be deemed to beneficially own the shares held by the Master Fund, and Cormorant and Ms. Chen may be deemed to beneficially own the shares held by the Master Fund and the Account.
  2. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  3. Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $10.00 to $10.90 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 106,771 were purchased for the Master Fund and 21,636 shares were purchased for the Account. As of November 29, 2016, the Master Fund held 2,924,147 shares, and the Account held 584,205 shares.
  4. Represents the weighted average purchase price of shares purchased in a series of open market transactions on the transaction date at prices ranging from $9.75 to $10.25 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. Of these shares, 34,910 were purchased for the Master Fund and 7,074 shares were purchased for the Account. As of December 1, 2016, the Master Fund held 2,959,057 shares, and the Account held 591,279 shares.